United Therapeutics has decided to discontinue the development of esuberaprost for the treatment of PAH.
Fresenius Kabi announced the launch of Adenosine Injection in single-dose Simplist ready-to-administer prefilled syringes.
The FDA issued a warning to Inova Genomics Laboratory for the illegal marketing of pharmacogenetic tests for predicting medication response to antidepressants, opioids, cancer therapy, anesthesia, and diabetes treatments.
The FDA has released a list of 40 ARBs that do not contain any known nitrosamine impurities.
Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 in San Diego.
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.
The American Diabetes Association (ADA) has updated the Standards of Medical Care in Diabetes for 2019 based on recently published research.
Sandoz announced the launch of Treprostinil Injection, the first AP rated generic version of United Therapeutics’ Remodulin.
Rivaroxaban found to reduce risk of stroke.